Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy
Topical Androgen Receptor Inhibitor for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy
Sponsor: Stanford University
Listed as NCT05891795, this observational or N/A phase trial focuses on Acne Vulgaris and remains ongoing. Sponsored by Stanford University, it has been updated 9 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
May 4, 2026 — Present [daily]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting · Phase: PHASE1/PHASE2 → None
-
Jun 2025 — May 2026 [monthly]
Recruiting PHASE1/PHASE2
-
Nov 2024 — Jun 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE1/PHASE2
▶ Show 4 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Mar 2024 — Jun 2024 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Jul 2023 — Mar 2024 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
Mechanism-based acne treatment for transgender patients receiving testosterone currently does not exist and is an unmet medical need. This study explores clascoterone to treat testosterone induced acne. Many treatments we use to treat acne in females cannot be used in transgender males because they interfere with hormone therapy. Androgens have been associated with the development of acne vulgaris. Recently, a topical androgen receptor inhibitor cream (clascoterone) has been FDA-approved for the treatment of acne. However, clinical trials of clascoterone have excluded participants on exogenous hormones. Clascoterone has been hypothesized to be effective in the treatment of acne in transgender male participants on masculinizing hormone therapy, but it has never been studied or reported in the literature.
Contact Information
- Stanford University
For direct contact, visit the study record on ClinicalTrials.gov .